[TGTX] TG Therapeutics Thesis 2026: An Anti-CD20 MS Drug Scales Toward Profitability and a CAR-T Optionality Pipeline

Key Takeaways

• TG Therapeutics, Inc. (NASDAQ: TGTX) is expected to close FY2025 with selected various aggregate net product revenue of roughly $500-700M (rapid growth from a small 2024 base) and aggregate adjusted EPS in the area of $0.10-0.70, with the company turning from a heavy-loss biotech into an emerging-profit specialty biopharma, under President & CEO Michael S. Weiss (~10+ year tenure, an investor-turned-operator who has run TG through its long, contentious development of ublituximab).
• The first deep-dive — the BRIUMVI (ublituximab) commercial franchise in relapsing multiple sclerosis (MS) — covers the anti-CD20 monoclonal antibody approved by the FDA in December 2022 and launched in early 2023 (with EU approval in 2023) as a 1-hour infusion every six months for adults with relapsing forms of MS — a category dominated by Roche's Ocrevus (ocrelizumab) but where BRIUMVI's shorter infusion time, glycoengineered profile and price positioning have driven rapid early-launch share gains; FY2026 catalyst is continued US prescription growth, ex-US (EU and other) ramp, infusion-site expansion (subcutaneous formulation development), and a path to ~$1B+ revenue run-rate.
• The second deep-dive — the pipeline and capital-allocation optionality — covers earlier-stage assets including azer-cel (allogeneic CD19 CAR-T for autoimmune diseases including lupus, anti-Synthetase and other rare-autoimmune indications, acquired from Precision BioSciences (DTIL) in 2023) and TG-1701 (a BTK inhibitor for autoimmune/oncology), plus a deepening US specialty commercial infrastructure that creates optionality for in-licensing additional autoimmune or MS-adjacent assets; FY2026 catalyst is azer-cel clinical data in autoimmune indications and any pipeline expansion.
• Capital position is now self-funding: no dividend, no buybacks of consequence, selected various aggregate cash, equivalents and short-term investments of ~$300-500M+, modest convertible debt (selected various aggregate ~$120-160M nominal), no material leverage of consequence (the company has flipped from years of dilution to a path of cash generation), and roughly ~155-165M shares outstanding.
• FY2026 catalysts: US BRIUMVI prescription growth and total revenue toward $700M-1.0B+, ex-US (Europe, ex-EU) launch ramp, the subcutaneous BRIUMVI formulation (a major convenience differentiator versus Ocrevus's competing SC), infusion-site/coding tailwinds (Buy & Bill economics), azer-cel autoimmune data, possible in-licensing, free-cash-flow inflection (operating leverage with revenue scaling), and the company's first full-year profitability print.

Company Background

TG Therapeutics, Inc., headquartered in Morrisville, North Carolina (with a New York presence), is a commercial-stage biopharmaceutical company that, after a decade-long, often-contentious development path, achieved a transformative success with the December 2022 FDA approval of BRIUMVI (ublituximab) — an anti-CD20 monoclonal antibody — for relapsing forms of multiple sclerosis in adults. The company traces back to the 2012 formation of TG Therapeutics by Michael S. Weiss (a former investment banker and biopharma investor) and an earlier reverse-merger with Manhattan Pharmaceuticals. For most of the 2010s and early 2020s, TG was a small clinical-stage company developing ublituximab and other assets (initially in oncology — chronic lymphocytic leukemia / CLL — under the rationale that the next-generation glycoengineered anti-CD20 antibody would compete with Roche's Rituxan/rituximab) and trading on the binary outcomes of those programs; the CLL/oncology path had setbacks (a complete response letter and a withdrawn US oncology BLA in 2023 over methodology concerns), but MS — pivoted to in the late 2010s — delivered the ULTIMATE I & II Phase 3 trials (vs interferon beta-1a, positive on annualized relapse rate and MRI endpoints) that supported the December 2022 BRIUMVI approval, followed by the EU approval in 2023. BRIUMVI launched in early 2023 and has ramped rapidly — substantially faster than initial Street expectations — into a multi-billion-dollar relapsing-MS market. Behind BRIUMVI, TG holds an autoimmune-CAR-T optionality position via the 2023 acquisition of azer-cel (an allogeneic CD19 CAR-T cell therapy) from Precision BioSciences (DTIL) for use in lupus, anti-Synthetase Syndrome and other autoimmune indications, plus a BTK inhibitor (TG-1701) and earlier-stage molecules. Geography: US-led commercialization with growing European and select ex-EU launches. The capital structure has flipped from years of dilution to a path of self-funded growth. Risks: BRIUMVI competitive pressure in MS (Ocrevus dominant; new entrants including the subcutaneous Ocrevus, BTK inhibitors, oral DMTs); reimbursement/payer dynamics; ex-US launch execution; azer-cel clinical risk; and the long tail of any pipeline development.

The BRIUMVI (Ublituximab) Commercial Franchise in Relapsing Multiple Sclerosis

The thesis is BRIUMVI, the BRIUMVI launch, and BRIUMVI ramp. BRIUMVI (ublituximab) is a glycoengineered anti-CD20 monoclonal antibody — engineered for enhanced antibody-dependent cellular cytotoxicity (ADCC) — that depletes B cells (a key driver of MS pathology), administered as a 1-hour IV infusion every six months after an initial loading dose. The clinical rationale: the B-cell-depletion class (Roche's Ocrevus/ocrelizumab, Novartis's Kesimpta/ofatumumab) has revolutionized relapsing-MS treatment over the past decade by significantly outperforming traditional first-line therapies on relapse-rate and disability-progression endpoints, and the class has rapidly become first-line standard of care; BRIUMVI's differentiation is a shorter infusion time (1 hour vs Ocrevus's ~3.5-hour first infusion / ~2 hour subsequent), a glycoengineered design (potentially more potent), and competitive pricing (the launch-list price comes in modestly below Ocrevus, supporting payer access and Buy & Bill economics). The launch: US BRIUMVI launched in January 2023 and has ramped faster than initial Street expectations, with net product revenue growing from selected various aggregate ~$8M in 1Q23 → ~$50M in 4Q23 → ~$80-100M in 1Q24 → $100M+/quarter by 2024 year-end → toward selected various aggregate ~$130-180M+/quarter in 2025 (a clearly steepening curve). Drivers include (a) payer access (covered by major commercial and Medicare formularies), (b) buy-and-bill economics that work well for infusion-administering neurology practices, (c) switch dynamics from oral DMTs and earlier-generation IV agents (Tysabri, etc.), and (d) Ocrevus-naive new starts. FY2025 dynamics: revenue growing ~$100M+/quarter sequentially, payer broadening, infusion-center capacity adding, gross-to-net stabilizing, operating costs growing slower than revenue (gross margin ~95%+ — biologic), and the company moving toward and through breakeven. FY2026 catalyst: continued US revenue growth (toward ~$700M-1.0B+ annual run-rate), ex-US ramp (EU launches underway, with country-by-country reimbursement), the subcutaneous BRIUMVI formulation development (Phase 3 underway — would dramatically expand the addressable population by enabling at-home dosing, matching Kesimpta's convenience and competing with the Ocrevus SC formulation Roche has now launched), label expansion possibilities, and operating leverage. Risks/competitors: Roche's Ocrevus (the entrenched leader — Ocrevus Zunovo SC launched 2024), Novartis's Kesimpta (the subcutaneous anti-CD20), BTK inhibitors (Sanofi's tolebrutinib, Roche's fenebrutinib — emerging class), oral DMTs (Tecfidera, Mavenclad, Mayzent, Vumerity), and a continued stream of new MS therapies; pricing/payer pressure; and execution of the subcutaneous BRIUMVI program.

The Pipeline (Azer-Cel, TG-1701) Plus the Capital and Commercial Optionality

The second leg is the pipeline plus the commercial infrastructure as a platform for optionality. Azer-cel (azercabtagene zapreleucel): an allogeneic ("off-the-shelf") CD19 CAR-T cell therapy acquired by TG from Precision BioSciences (DTIL) in late 2023 for an upfront cash payment plus future milestones; azer-cel was originally developed as an oncology cell therapy for B-cell malignancies but is now being repurposed by TG for B-cell-driven autoimmune diseases — principally systemic lupus erythematosus (SLE), lupus nephritis, anti-Synthetase Syndrome, and other rare autoimmune conditions — where the autologous CAR-T approach has shown striking early-phase clinical signals (deep B-cell depletion → drug-free remissions in small Phase 1 studies from academic groups and competitors like Cabaletta (CABA) and Kyverna (KYTX)); azer-cel's allogeneic design — using donor cells rather than the patient's own — could provide scale and economics advantages over autologous CAR-T if clinical data hold (lower cost, off-the-shelf availability, no apheresis). TG is initiating azer-cel autoimmune trials and gathering early data; this is high-optionality, high-uncertainty pipeline value. TG-1701 is an oral, brain-penetrant BTK inhibitor in earlier-stage development for autoimmune and oncology indications (the BTK class is competitive — Sanofi's tolebrutinib in MS, AstraZeneca's calquence in oncology). The commercial infrastructure as a platform: TG has built a US specialty neurology salesforce and a payer/reimbursement organization that gives it an asset-light way to in-license or acquire additional autoimmune or MS-adjacent products — a meaningful "platform" optionality. FY2025 dynamics: azer-cel autoimmune trial initiation, early academic-data crosstalk in lupus, TG-1701 preclinical/early-clinical progression. FY2026 catalyst: azer-cel clinical data (any early efficacy signals would be transformative), TG-1701 data, possible in-licensing or partnerships, and any acquisition activity. Risks/competitors: azer-cel clinical failure (allogeneic CAR-Ts have had mixed clinical success vs autologous — durability and persistence concerns), competing autoimmune CAR-T programs (Cabaletta (CABA), Kyverna (KYTX), Bristol-Myers's Breyanzi being explored, Novartis's Kymriah, plus T-cell engagers from Astellas-Iveric/Annexon and others), the broader autoimmune market where biologics like rituximab, anti-CD19 (inebilizumab/Uplizna) and JAK inhibitors compete, and execution risk on TG's first cell-therapy program. The pipeline is meaningful upside optionality on top of an increasingly real BRIUMVI franchise.

Capital Position + Balance Sheet

TG runs a now-self-funding balance sheet emerging from years of dilution. The company pays no dividend and conducts no buybacks of consequence (cash is reinvested in BRIUMVI commercialization, ex-US launch, azer-cel development and capital strength). Cash, cash equivalents and short-term investments are selected various aggregate ~$300-500M+ — a meaningful cushion bolstered by improving operating cash flow as BRIUMVI revenue scales (TG flipped to operating-profit positive territory during 2024 and is on a trajectory of self-funded growth). Debt is modest — selected various aggregate ~$120-160M of convertible senior notes (manageable, with the conversion price relevant to dilution math), no material term loans — so net debt is selected various aggregate near zero or net-cash. The share count is selected various aggregate ~155-165M (heavy historical dilution from years of equity financings, but the issuance pace has slowed dramatically as the cash position has built). The principal balance-sheet considerations are the trajectory of operating cash flow as BRIUMVI revenue grows over a relatively fixed operating-cost base, the convertible-debt dilution dynamics, the cash-allocation decisions on azer-cel investment and any in-licensing, and the historical large share-count creep (which is now stabilizing). A future capital return (a buyback) would be a meaningful confidence signal; a dividend remains unlikely near-term.

Key Core Metrics

• Net product revenue: selected various aggregate ~$500-700M FY2025 (entirely BRIUMVI; rapid growth from $292M in 2024)
• Net income / adj. EPS: selected various aggregate ~$0.10-0.70 adj. EPS FY2025 (flipped to profitability)
• Gross margin: ~95%+ (biologic)
• Operating cash flow: selected various aggregate positive and growing
• BRIUMVI (ublituximab): glycoengineered anti-CD20 monoclonal antibody; 1-hour IV infusion every 6 months
• FDA approval: December 2022 for relapsing forms of MS; EU approval 2023; US launch January 2023
• Quarterly BRIUMVI revenue trajectory: from ~$8M (1Q23) → ~$130-180M+ (mid-2025)
• Launch differentiation: shorter infusion (1 hour vs Ocrevus 2-3.5 hours), glycoengineered, competitive pricing
• Subcutaneous BRIUMVI: in development (Phase 3) — the major convenience-expansion catalyst
• Direct competitors in MS B-cell-depletion class: Ocrevus (Roche, ocrelizumab; Ocrevus Zunovo SC); Kesimpta (Novartis, ofatumumab SC); BTK inhibitors emerging (Sanofi's tolebrutinib, Roche's fenebrutinib)
• Pipeline:
  • Azer-cel (azercabtagene zapreleucel) — allogeneic CD19 CAR-T for autoimmune diseases (SLE, lupus nephritis, anti-Synthetase, other) — acquired from Precision BioSciences (DTIL) 2023
  • TG-1701 — oral BTK inhibitor for autoimmune/oncology
• Commercial infrastructure: US specialty neurology salesforce + payer/reimbursement org — platform for in-licensing
• Geography: US-led + EU launches underway + ex-EU rollout
• Cash + equivalents + short-term investments: selected various aggregate ~$300-500M+
• Convertible debt: selected various aggregate ~$120-160M nominal (manageable)
• Net debt: selected various aggregate near zero or net-cash
• Dividend: none; Buybacks: none of consequence — cash to commercialization + pipeline
• Shares outstanding: selected various aggregate ~155-165M
• CEO: Michael S. Weiss (President & CEO, ~10+ year tenure; investor-turned-operator)

Market Evaluation

At roughly ~$25-45 per share on ~155-165M shares, TG Therapeutics carries an equity value of selected various aggregate ~$4-7B (and an enterprise value broadly similar net of cash and convertible debt) — a valuation that prices an increasingly real BRIUMVI franchise (the multi-quarter trajectory toward $1B+ annual revenue) plus optionality on azer-cel and the broader pipeline; on EV/sales the multiple is roughly ~6-12x against FY2025 revenue, justified-by-bulls by the growth rate and the path to mid-teens-or-higher P/E once profitability scales. The comp set: in MS — Biogen (BIIB) (legacy MS leader), Sanofi (SNY) (tolebrutinib in MS), Novartis (NVS) (Kesimpta), Roche (Ocrevus, private/Swiss), Bristol-Myers (BMY) (Zeposia); in commercial-stage neurology/specialty biopharma — Vertex (VRTX) (pain), Argenx (ARGX) (autoimmune-FcRn — Vyvgart franchise), Apellis (APLS), Insmed (INSM), Krystal Biotech (KRYS); in autoimmune-CAR-T — Cabaletta Bio (CABA) and Kyverna Therapeutics (KYTX) (azer-cel comp set). FY2026 base case: selected various aggregate ~$700M-1.0B+ revenue + ~$0.50-1.20 adj. EPS + continued US BRIUMVI growth + EU launch ramping + azer-cel data starting to emerge + self-funded growth + cash position building + the subcutaneous BRIUMVI Phase 3 progressing — scaling profitability. Bull case: selected various aggregate ~$1.0-1.4B+ revenue + ~$1.50-2.50+ adj. EPS on stronger BRIUMVI growth (subcutaneous formulation approved and launched, ex-US ramp accelerating, BTK-inhibitor delays in MS letting BRIUMVI/anti-CD20s grab more share), azer-cel autoimmune data positive (a major asymmetric upside), pipeline expansion via in-licensing, FCF inflection, an eventual buyback initiation, and a re-rating. Bear case: selected various aggregate ~$450-650M revenue + ~$(0.10)-0.30 adj. EPS on Ocrevus Zunovo SC + Kesimpta intensifying competitive pressure, US share losses, ex-US disappointment, azer-cel failing in autoimmune trials, the SC BRIUMVI program slipping or competing poorly, and a de-rating. The thesis turns on the BRIUMVI commercial pipeline (US prescription growth + ex-US ramp + subcutaneous formulation + payer/Buy-and-Bill dynamics + share dynamics in the B-cell-depletion class) plus the pipeline-and-commercial-optionality pipeline (azer-cel autoimmune CAR-T + TG-1701 BTK + the platform for in-licensing) plus operating leverage to profitability plus a defensive cash position plus Michael Weiss's continued execution of the BRIUMVI commercial and pipeline-expansion playbook.